Fentanyl for breakthrough pain: A systematic review

Expert Review of Neurotherapeutics

Volumn 11, Issue 8, 2011, Pages 1197-1216

  Davis, Mellar P ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

fentanyl; global efficacy; intranasal; pain relief; summation of pain intensity differences; transmucosal

Indexed keywords

ALFENTANIL; CODEINE; FENTANYL; FENTANYL CITRATE; HYDROMORPHONE; IBUPROFEN; METHADONE; METHOXYFLURANE; MORPHINE; NALTREXONE; ONSOLIS; OXYCODONE; PARACETAMOL; PILOCARPINE; PLACEBO; RIFAMPICIN; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ANALGESIA; AREA UNDER THE CURVE; ASTHENIA; CONFUSION; CONSTIPATION; DISSOCIATION CONSTANT; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSGEUSIA; EPISTAXIS; FATIGUE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MOUTH DISEASE; MUCOSA TOXICITY; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PAIN; PAIN ASSESSMENT; PATIENT SELECTION; REVIEW; SINGLE DRUG DOSE; SOMNOLENCE; STEADY STATE; SYSTEMATIC REVIEW; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ACUTE PAIN; ADMINISTRATION, BUCCAL; ADMINISTRATION, INTRANASAL; ADMINISTRATION, MUCOSAL; ADMINISTRATION, ORAL; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; FENTANYL; HUMANS;

EID: 79961079553     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.63     Document Type: Review

References (130)

1. Banning A, Sjogren P, Henriksen H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 45(1), 45-48 (1991).
2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 41(3), 273-281 (1990). (Pubitemid 20187930)
3. Bruera E, MacMillan K, Hanson J et al. The Edmonton staging system for cancer pain: preliminary report. Pain 37(2), 203-209 (1989). (Pubitemid 19136148)
4. Mercadante S. Predictive factors and opioid responsiveness in cancer pain. Eur. J. Cancer 34(5), 627-631 (1998). (Pubitemid 28218935)
5. Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat. Rev. 24(6), 425-432 (1998). (Pubitemid 29121682)
6. McQuay HJ, Jadad AR. Incident pain. Cancer Surv. 21, 17-24 (1994). (Pubitemid 24355811)
7. Davies A, Zeppetella G, Andersen S et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur. J. Pain DOI: 10.1016/j. ejpain.2010.12.004 (2011) (Epub ahead of print).
8. Davies A, Dickman A, Reid C et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J. Pain 13(4), 331-338 (2009).
9. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 41(3), 273-281 (1990). (Pubitemid 20187930)
10. Grape S, Schug SA, Lauer S et al. Formulations of fentanyl for the management of pain. Drugs 70(1), 57-72 (2010).
11. Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin. Pharmacokinet. 8(5), 422-446 (1983). (Pubitemid 13009122)
12. Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 90(2), 576-599 (1999). (Pubitemid 29071528)
13. Scholz J, Steinfath M, Schulz M. Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update. Clin. Pharmacokinet. 31(4), 275-292 (1996). (Pubitemid 26340663)
14. Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid selection. Anesthesiology 74(1), 53-63 (1991).
15. Henthorn TK, Liu Y, Mahapatro M et al. Active transport of fentanyl by the blood-brain barrier. J. Pharmacol. Exp. Ther. 289(2), 1084-1089 (1999). (Pubitemid 29191270)
16. Bower S, Hull CJ. Comparative pharmacokinetics of fentanyl and alfentanil. Br. J. Anaesth. 54(8), 871-877 (1982). (Pubitemid 12042307)
17. Waters CM, Avram MJ, Krejcie TC et al. Uptake of fentanyl in pulmonary endothelium. J. Pharmacol. Exp. Ther. 288(1), 157-163 (1999). (Pubitemid 29113486)
18. Waters CM, Krejcie TC, Avram MJ. Facilitated uptake of fentanyl, but not alfentanil, by human pulmonary endothelial cells. Anesthesiology 93(3), 825-831 (2000).
19. Upton RN, Grant C, Martinez AM et al. Recirculatory model of fentanyl disposition with the brain as the target organ. Br. J. Anaesth. 93(5), 687-697 (2004). (Pubitemid 39445551)
20. Kharasch ED, Hoffer C, Whittington D. Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate. Anesthesiology 101(3), 738-743 (2004). (Pubitemid 39121654)
21. Labroo RB, Paine MF, Thummel KE et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab. Dispos. 25(9), 1072-1080 (1997). (Pubitemid 27396495)
22. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet. 41(9), 661-680 (2002).
23. Shafer SL. More on pharmacokinetics with a pocket calculator. Anesthesiology 74(3), 631 (1991).
24. Zernig G, Issaevitch T, Broadbear JH et al. Receptor reserve and affinity of μ opioid agonists in mouse antinociception: correlation with receptor binding. Life Sci. 57(23), 2113-2125 (1995).
25. Sirohi S, Dighe SV, Walker EA et al. The analgesic efficacy of fentanyl: relationship to tolerance and μ-opioid receptor regulation. Pharmacol. Biochem. Behav. 91(1), 115-120 (2008).
26. Fine PG, Messina J, Xie F et al. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J. Pain Symptom Manage. 40(5), 747-760 (2010).
27. Rauck RL, Tark M, Reyes E et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr. Med. Res. Opin. 25(12), 2877-2885 (2009).
28. Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today 44(1), 41-54 (2008). (Pubitemid 351397412)
29. Segal T, Hale M, Jhangiani H et al. Patients' experience with fentanyl effervescent buccal tablets: interim analysis of a long-term, multicenter, open-label study in cancer-related breakthrough pain. J. Pain 7(4), 35 (2006).
30. Farrar JT, Portenoy RK, Berlin JA et al. Defining the clinically important difference in pain outcome measures. Pain 88(3), 287-294 (2000).
31. Dworkin RH, Turk DC, Farrar JT et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113(1-2), 9 (2005).
32. Farrar JT, Polomano RC, Berlin JA et al. A comparison of change in the 0-10 numeric rating scale to a pain relief scale and global medication performance scale in a short-term clinical trial of breakthrough pain intensity. Anesthesiology 112(6), 1464-1472 (2010).
33. Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352(9128), 609-613 (1998). (Pubitemid 28380142)
34. Schulz KF, Chalmers I, Hayes RJ et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273(5), 408-412 (1995).
35. Darwish M, Hamed E, Messina J. Fentanyl buccal tablet for the treatment of breakthrough pain: pharmacokinetics of buccal mucosa delivery and clinical efficacy. Perspect. Medicin. Chem. 4, 11-21 (2010).
36. Streisand JB, Varvel JR, Stanski DR et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 75(2), 223-229 (1991).
37. Aronoff GM, Brennan MJ, Pritchard DD et al. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med. 6(4), 305-314 (2005). (Pubitemid 41725955)
38. Shaiova L, Lapin J, Manco LS et al. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Support. Care Cancer 12(4), 268-273 (2004). (Pubitemid 38660750)
39. Davies AN, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J. Pain Symptom Manage. 30(6), 496-497 (2005). (Pubitemid 41821200)
40. Streisand JB, Busch MA, Egan TD et al. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 88(2), 305-309 (1998). (Pubitemid 28081188)
41. Egan TD, Sharma A, Ashburn MA et al. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology 92(3), 665-673 (2000). (Pubitemid 30130168)
42. Lichtor JL, Sevarino FB, Joshi GP et al. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth. Analg. 89(3), 732-738 (1999). (Pubitemid 29409831)
43. Mercadante S, Villari P, Ferrera P et al. The use of opioids for breakthrough pain in acute palliative care unit by using doses proportional to opioid basal regimen. Clin. J. Pain 26(4), 306-309 (2010).
44. Lu J, Bailey P. Dose-related respiratory pharmacology of oral transmucosal fentanyl citrate (OTFC(R)) versus intravenous morphine: a randomized, double-blind, double-dummy study. ASA Annual Meeting Abstracts. Local Anesthesia and Pain 99(3A), Abstract A967 (2003).
45. Sharar SR, Carrougher GJ, Selzer K et al. A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. J. Burn Care Rehabil. 23(1), 27-31 (2002). (Pubitemid 34072722)
46. Schechter NL, Weisman SJ, Rosenblum M et al. The use of oral transmucosal fentanyl citrate for painful procedures in children. Pediatrics 95(3), 335-339 (1995).
47. Schutzman SA, Burg J, Liebelt E et al. Oral transmucosal fentanyl citrate for premedication of children undergoing laceration repair. Ann. Emerg. Med. 24(6), 1059-1064 (1994). (Pubitemid 24368142)
48. Sharar SR, Bratton SL, Carrougher GJ et al. A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. J. Burn Care Rehabil. 19(6), 516-521 (1998). (Pubitemid 28549805)
49. Robert R, Brack A, Blakeney P et al. A double-blind study of the analgesic efficacy of oral transmucosal fentanyl citrate and oral morphine in pediatric patients undergoing burn dressing change and tubbing. J. Burn Care Rehabil. 24(6), 351-355 (2003). (Pubitemid 37444509)
50. Mahar PJ, Rana JA, Kennedy CS et al. A randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries. Pediatr. Emerg. Care 23(8), 544-548 (2007). (Pubitemid 47339795)
51. Wheeler M, Birmingham PK, Dsida RM et al. Uptake pharmacokinetics of the fentanyl oralet in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. Paediatr. Anaesth. 12(7), 594-599 (2002). (Pubitemid 35266464)
52. Hanks GW, Nugent M, Higgs CM et al. Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat. Med. 18(8), 698-704 (2004). (Pubitemid 39654548)
53. Christie JM, Simmonds M, Patt R et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J. Clin. Oncol. 16(10), 3238-3245 (1998). (Pubitemid 28481617)
54. Shaiova L, Lapin J, Manco LS et al. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Support. Care Cancer 12(4), 268-273 (2004). (Pubitemid 38660750)
55. Coluzzi PH, Schwartzberg L, Conroy JD Jr et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).Pain 91(1-2), 123-130 (2001). (Pubitemid 32274181)
56. Portenoy RK, Payne R, Coluzzi P et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79(2-3), 303-312 (1999). (Pubitemid 29076765)
57. Farrar JT, Cleary J, Rauck R et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J. Natl Cancer Inst. 90(8), 611-616 (1998). (Pubitemid 28204805)
58. Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J. Pain Symptom Manage. 35(5), 563-567 (2008).
59. Jekunen A, Cotterill-Jones C, Dewlan P et al. Dose linearity of inhaled fentanyl (FT) with comparative pharmacokinetics to transmucosal fentanyl (A).J. Clin. Oncol. 24(S18), S499 (2006).
60. Taylor DR, Webster LR, Chun SY et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC®, ACTIQ®).Pain Med. 8(3), 281-288 (2007). (Pubitemid 46443468)
61. Mercadante S, Villari P, Ferrera P et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br. J. Cancer 96(12), 1828-1833 (2007). (Pubitemid 46912022)
62. Hagen NA, Fisher K, Victorino C et al. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J. Palliat. Med. 10(1), 47-55 (2007). (Pubitemid 46238952)
63. Zeppetella G, Ribeiro MD. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst. Rev. CD004311 (2006).
64. Hanks GW, Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer 84(5), 587-593 (2001). (Pubitemid 32238990)
65. Mercadante S, Ferrera P, Arcuri E. The use of fentanyl buccal tablets as breakthrough medication in patients receiving chronic methadone therapy: an open label preliminary study. Support. Care Cancer 19(3), 435-438 (2010).
66. Bredenberg S, Duberg M, Lennernas B et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur. J. Pharm. Sci. 20(3), 327-334 (2003). (Pubitemid 37338538)
67. Darwish M, Kirby M, Jiang JG. Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin. Pharmacother. 8(13), 2011-2016 (2007). (Pubitemid 47514454)
68. Darwish M, Tempero K, Kirby M et al. Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin. Pharmacokinet. 44(12), 1279-1286 (2005). (Pubitemid 41832568)
69. Darwish M, Tempero K, Kirby M et al. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 μg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin. Ther. 28(5), 715-724 (2006). (Pubitemid 44173055)
70. Darwish M, Kirby M, Robertson P Jr et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J. Clin. Pharmacol. 47(3), 343-350 (2007). (Pubitemid 46294716)
71. Darwish M, Kirby M, Robertson P Jr et al. Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J. Clin. Pharmacol. 47(1), 56-63 (2007). (Pubitemid 44973998)
72. Darwish M, Kirby M, Jiang JG et al. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 μg in healthy subjects. Clin. Drug Invest. 28(1), 1-7 (2008). (Pubitemid 350274395)
73. Lennernas B, Hedner T, Holmberg M et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br. J. Clin. Pharmacol. 59(2), 249-253 (2005). (Pubitemid 40208864)
74. Weick JK, Tremmel L, Messina J et al. Finding an appropriate dose of fentanyl effervescent buccal tablets for relief of cancer-related breakthrough pain abstract 2011. J. Clin. Oncol.: ASCO Annual Meeting Proceedings 24(18S Part I), 484 (2006).
75. Wertheim M, Jhangiani H, Niebler G et al. Finding an effective dose of fentanyl effervescent buccal tablets: combined results of open-label titration. J. Clin. Oncol. 24(18S), S689 (2006).
76. Slatkin N, Charu V, Niebler G et al. Long-term tolerability of fentanyl effervescent buccal tablets: interim analysis in patients with cancer-related breakthrough pain. J. Clin. Oncol. 24(18S), S484 (2006).
77. Portenoy RK, Taylor D, Messina J et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin. J. Pain 22(9), 805-811 (2006). (Pubitemid 44627444)
78. Webster LR, Taylor D, Peppin J et al. Open-label study of fentanyl effervescent buccal tablets in patients with noncancer pain and breakthrough pain: patient preference assessment. J. Pain 7(4), 52 (2006).
79. Slatkin NE, Xie F, Messina J et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J. Support. Oncol. 5(7), 327-334 (2007). (Pubitemid 350055013)
80. Portenoy RK, Messina J, Xie F et al. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr. Med. Res. Opin. 23(1), 223-233 (2007). (Pubitemid 46191684)
81. Taylor D, Portenoy R, Messina J et al. A randomized, placebo-controlled study of fentanyl effervescent buccal tablets for relief of breakthrough pain in opioid-tolerant patients with cancer. J. Pain 7(4), 2 (2006).
82. Nalamachu S, Xie F, Messina J. Mood, functioning, and quality of life in opioid-tolerant patients with noncancer chronic pain and breakthrough pain: effect of fentanyl buccal tablet (FBT).J. Pain 8(4), S43 (2007).
83. Fine PG, Messina J, Xie F et al. Management of breakthrough pain (BTP) in opioid-tolerant patients with chronic low back pain or neuropathic pain: combined analysis of two randomized, double-blind studies of fentanyl buccal tablet (FBT).J. Pain 8(4), S43 (2007).
84. Simpson D, Messina J, Xie F et al. Management of breakthrough pain in opioid-tolerant patients with chronic low back pain or neuropathic pain: randomized, double-blind studies of efficacy and tolerability of fentanyl buccal tablet (FBT).J. Pain 8(4), S41 (2007).
85. Farrar JT, Michna E, Messina J et al. Impact of fentanyl buccal tablet on both patient and clinician ratings of patient function. J. Pain 9(4), 39 (2008).
86. Zeppetella G, Messina J, Xie F et al. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain. Pain Pract. 10(4), 287-293 (2010).
87. Lennernas B, Frank-Lissbrant I, Lennernas H et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized Phase II study. Palliat. Med. 24(3), 286-293 (2010).
88. Passik SD, Messina J, Golsorkhi A et al. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain. J. Pain Symptom Manage. 41(1), 116-125 (2011).
89. Ashburn M, Slevin K, Messina JXF. Fentanyl buccal tablet vs oxycodone immediate-release for the management of breakthrough pain in opioid-tolerant patients with chronic pain: patient disposition and dose titration. J. Pain 11(4), S49 (2010).
90. Fine PG, Narayana A, Passik SD. Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management. Pain Med. 11(7), 1024-1036 (2010).
91. Vasisht N, Gever LN, Tagarro I et al. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med. 11(7), 1017-1023 (2010).
92. Vasisht N, Gever LN, Tagarro I et al. Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J. Clin. Pharmacol. 50(7), 785-791 (2010).
93. Vasisht N, Gever LN, Tagarro I et al. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin. Drug Invest. 29(10), 647-654 (2009).
94. Rauck RL, Tark M, Reyes E et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr. Med. Res. Opin. 25(12), 2877-2885 (2009).
95. Dale O. Intranasal administration of opioids/fentanyl - physiological and pharmacological aspects. Eur J. Pain Suppl. 4(3), 187 (2010).
96. Kaasa S, Moksnes K, Nolte T et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J. Opioid Manag. 6(1), 17-26 (2010).
97. Foster D, Upton R, Christrup L et al. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann. Pharmacother. 42(10), 1380-1387 (2008).
98. Nave R, Sides EH, Colberg T, Lophaven SO, Meng X, Lahu G, Schmitt H. Higher systemic bioavailability and faster absorption of intranasal fentanyl spray (INFS) compared to ACTIQ (OTFC) in healthy subjects. Eur. J. Pain 13, S206 (2009).
99. Fisher A, Watling M, Smith A et al. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int. J. Clin. Pharmacol. Ther. 48(2), 138-145 (2010).
100. Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics after administration of 100ug intranasal fentanyl spray (1 dose vs. 2 doses) in non-elderly and elderly healthy subjects. Eur. J. Pain 13, S207 (2009).
101. Nave R, Sides EH, Colberg T et al. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior administration of oxymetazoline. Eur. J. Pain 13, S207 (2009).
102. Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schnmitt H. Pharmacokinetics of intranasal fentanyl spray (INFS) in subjects with common cold. Eur. J. Pain 13, S55-S285 (2009).
103. Zeppetella G. An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. J. Pain Symptom Manage. 20(4), 253-258 (2000).
104. Colberg T, Nolte T, Oronska A et al. Titration of intranasal fentanyl for breakthrough pain in patients with cancer: evidence for dose proportionality vs. background analgesia. Ann. Oncol. 19(Suppl. 8), 257-258 (2009).
105. Kaasa S, Marchesini C, Kaczmarek Z et al. Tolerability and safety of intranasal fentanyl treatment for breakthrough pain in patients with cancer: four-month follow-up. Ann. Oncol. 19(Suppl. 8), 257 (2009).
106. Nolte T, Marchesini C, Oronska A et al. Efficacy of intranasal fentanyl for breakthrough pain in patients with cancer: results of a Phase III trial. Ann. Oncol. 19(Suppl. 8), 254 (2009).
107. Christrup LL, Foster D, Popper LD et al. Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study. Clin. Ther. 30(3), 469-481 (2008). (Pubitemid 351483922)
108. Kress HG, Colberg T. Titration of intranasal fentanyl spray (INFS) for breakthrough pain in cancer patients: evidence for dose proportionality vs background analgesia. Eur. J. Pain 13, S197 (2009).
109. Mercadante S, Radbruch L, Davies A et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr. Med. Res. Opin. 25(11), 2805-2815 (2009).
110. Portenoy RK, Burton AW, Gabrail N et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 151(3), 617-624 (2010).
111. Kress HG, Oronska A, Kaczmarek Z et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a Phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin. Ther. 31(6), 1177-1191 (2009).
112. Vissers D, Stam W, Nolte T et al. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr. Med. Res. Opin. 26(5), 1037-1045 (2010).
113. Veldhorst-Janssen NM, Fiddelers AA, van der Kuy PH et al. Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: a prospective, randomized, double-blind, placebo-controlled study. Clin. Ther. 32(7), 1427-1436 (2010).
114. Younge PA, Nicole MF, Kendall JM. A prospective randomised pilot comparison of intranasal fentanyl and intramuscular morphine for analgesia in children presenting to the emergency department with clinical fractures. Emerg. Med. (Fremantle) 11, 90-94 (1999).
115. Borland ML, Jacobs I, Geelhoed G. Intranasal fentanyl reduces acute pain in children in the emergency department: a safety and efficacy study. Emerg. Med. (Fremantle) 14(3), 275-280 (2002).
116. Borland ML, Bergesio R, Pascoe EM et al. Intranasal fentanyl is an equivalent analgesic to oral morphine in paediatric burns patients for dressing changes: a randomised double blind crossover study. Burns 31(7), 831-837 (2005). (Pubitemid 41394138)
117. Borland M, Jacobs I, King B et al. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann. Emerg. Med. 49(3), 335-340 (2007).
118. Borland ML, Clark LJ, Esson A. Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department. Emerg. Med. Australas. 20(6), 515-520 (2008).
119. Chung S, Lim R, Goldman RD. Intranasal fentanyl versus placebo for pain in children during catheterization for voiding cystourethrography. Pediatr. Radiol. 40(7), 1236-1240 (2010).
120. Crellin D, Ling RX, Babl FE. Does the standard intravenous solution of fentanyl (50 μg/ml) administered intranasally have analgesic efficacy? Emerg. Med. Australas. 22(1), 62-67 (2010).
121. Cole J, Shepherd M, Young P. Intranasal fentanyl in 1-3-year-olds: a prospective study of the effectiveness of intranasal fentanyl as acute analgesia. Emerg. Med. Australas. 21(5), 395-400 (2009).
122. Herd D, Borland M. Intranasal fentanyl paediatric clinical practice guidelines. Emerg. Med. Australas. 21(4), 335 (2009).
123. Fentanyl intranasal. Breakthrough cancer pain; unsafe packaging. Prescrire Int. 19(110), 251 (2010).
124. Nalamachu S, Narayana A, Janka L. Long-term dosing, safety, and tolerability of fentanyl buccal tablet in the management of noncancer-related breakthrough pain in opioid-tolerant patients. Curr. Med. Res. Opin. 27(4), 751-760 (2011).
125. Wong S, Mundy L, Drake R et al. The prevalence of fentanyl in drug-related deaths in Philadelphia 2004-2006. J. Med Toxicol. 6(1), 9-11 (2010).
126. Center for Disease Control and Prevention (CDC).Nonpharmaceutical fentanyl-related deaths - multiple states, April 2005- March 2007. MMWR Morb. Mortal. Wkly Rep. 57(29), 793-796 (2008).
127. Schumann H, Erickson T, Thompson T et al. Fentanyl epidemic in Chicago, Illinois and surrounding Cook County. Clin. Toxicol. 46(6), 501-506 (2008). (Pubitemid 351913758)
128. Fodale V, Mafrica F, Santamaria L et al. Killer fentanyl: is the fear justified? Expert Opin. Drug Saf. 7(3), 213-217 (2008).
129. Henderson G. Fentanyl-related deaths: demographics, circumstances, and toxicology of 112 cases. J. Forensic Sci. 36(2), 422-433 (1991).
130. American Pharmacists Association. White paper on designing a risk evaluation and mitigation strategies (REMS) system to optimize the balance of patience access, medication safety, and impact on the health care system. J. Am. Pharm. Assoc. 49(6), 729-743 (2003).